Multaq® Liver, Lung, and Kidney Damage

The heart rhythm drug Multaq® has been linked to severe liver damage, liver failure, and the need for a liver transplant in some users. Multaq has also been linked to kidney failure and lung toxicity including interstitial lung disease and pulmonary fibrosis.

Following a safety review of the drug, U.S. Food and Drug Administration (FDA) warned that Multaq increases the risk of serious cardiovascular events, including death, when used by patients in permanent atrial fibrillation (AF).

If you suffered from liver, lung, or kidney damage while taking Multaq, our drug injury lawyers at Cory Watson Attorneys want to help. Give us a call at (877) 562-0000 or fill out our free consultation form to get started now.

What is Multaq® used for?

Multaq (dronedarone) is in a class of medications called antiarrhythmics, which are designed to help the heart to beat normally.

Multaq is used to treat people who have had atrial fibrillation (a heart rhythm disorder that may cause fast and irregular heartbeat) or atrial flutter (a heart rhythm disorder that may cause the heart to beat very fast) within the past six months and who also have other conditions that increase the risk that they will develop heart problems.

Multaq is marketed as decreasing the risk that people who have these conditions will need to be hospitalized to treat heart problems.

Is Multaq® dangerous?

The FDA warned that some patients using Multaq have suffered severe liver injury and liver failure leading to liver transplant. Post-marketing cases of kidney failure, interstitial lung disease, and pulmonary fibrosis have also been reported.

The FDA has notified healthcare professionals that a Multaq safety study was halted early after the data monitoring committee found a two-fold increase in death, as well as two-fold increases in stroke and hospitalization for heart failure in patients receiving Multaq compared to patients taking a placebo.

What does Multaq® look like?

Multaq is a white film-coated tablet that should be taken by mouth, usually two times a day with a meal. The standard dose is 400 mg twice a day, regardless of age or weight. There is no generic version.

How many people have taken Multaq®?

The FDA has reported that over 500,000 Multaq prescriptions were dispensed and over 150,000 patients filled Multaq prescriptions at outpatient retail pharmacies in the United States.

What is being done to protect consumers?

The FDA added warnings about the risk for liver damage, kidney failure, and lung disease to the label of Multaq and required over six label changes in just the first few years it was on the market.
The agency recommended patients should contact their doctor if they experience signs of liver injury, including nausea, vomiting, and fever. If doctors suspect toxicity issues, the patient should discontinue Multaq use and undergo a liver enzyme test.

The onset of dyspnea (shortness of breath) or non-productive cough may be related to pulmonary toxicity, such as interstitial lung disease or pulmonary fibrosis, and patients should be carefully evaluated because current or earlier Multaq use may have been the cause.

We Want to Help

If you took Multaq and received treatment for liver damage, liver failure, kidney failure, interstitial lung disease or pulmonary fibrosis, or if a loved one took Multaq and died from liver problems, kidney problems, or lung problems contact our firm immediately. Our attorneys are working to help Multaq victims get the help they need. Pick up the phone and call us at (877) 562-0000 or fill out our free consultation form to get started.

*Cory Watson Attorneys is no longer accepting Multaq cases.

Multaq® is a registered trademark of Sanofi-Aventis and is used here only to identify the product in question. This law firm is not associated with, sponsored by, or affiliated with the Food and Drug Administration or Sanofi-Aventis.